Novel Technologies to assess Gut Health Claims for Carbohydrates Subthema: 2 - Characterization of biological effects of carbohydrates Naam trekker: UJF.

Slides:

Advertisements

Similar presentations

CONVEGNO ITALIAN FOOD FOR LIFE FIERA DI PARMA, 8 MAGGIO 2008 FEDERALIMENTARE Servizi S.r.l. FOOD & HEALTH PILLAR COORDINATOR: Dr. Andrea Borsari – Granarolo.

Advertisements

Starter Read your tasks from the front of your folders– Do you understand what you MUST complete by the end of the lesson?

Chung S. Park Animal Science Department North Dakota State University November, 2012 Canola Oil and Breast Cancer Research Projects.

V ITAMIN D Monica Durham Rahmina Mutlib. V ITAMIN D Vitamin D is a fat soluble vitamin Synthesized by the body after exposure to UV rays or obtained from.

Children Aged 5 to

UAB Metabolomics Symposium December 12, 2012 Christopher B. Newgard, Ph.D. Sarah W. Stedman Nutrition and Metabolism Center Department of Pharmacology.

1 Aflatoxin exposure, health impacts, risk assessment and database Aflatoxin Stakeholders’ Workshop 3-4 December, 2012 Dar es Salaam, Tanzania.

Walter Lab: Gut microbiome and its interactions with metabolic disease

The Microbiome: What’s the immune system got to do with it?

Healthy Purdue Stacey L. Mobley, PhD, RD, CNSD Assistant Professor Department of Foods and Nutrition A Platform for Research in Disease Prevention and.

Disease X in 1985 No Data

University of Turku Department of Biochemistry Jukka-Pekka Suomela Biomarkers.

1 Rôle du microbiote intestinal dans le métabolisme des composés aromatiques polycycliques et hétérocycliques Role of intestinal microbiota in the metabolism.

1 Chemopreventive effects of pro- and prebiotics towards microbial bioactivation of ingested contaminants Inulin and Lactobacillus amylovorus supplemented.

NHS Breast Screening Programme (NHSBSP) – Forrest report To detect early, non-palpable disease in WOMEN Mammogram Every 3 years 50 and over (47-73.

Risk factors of Heart disease Dr. Mahmoudian.. Risk factors for coronary artery atherosclerosis Hyperlipidemia and dyslipidemia Hypertension Cigarette.

Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 13 – BIOMARKERS Summary and final notes.

ILSI Risk Science Institute Acrylamide Toxicity: Research to Address Key Data Gaps Presented by Dr. Stephen S. Olin ILSI Risk Science Institute.

Committee on Carcinogenicity (COC) Approach to Risk Assessment of Genotoxic Carcinogens David H. Phillips* COC Chairman Descriptive vs. Quantitative.

Optimizing Nutrition Therapy

Diet and Alzheimer’s disease Andy Smith School of Psychology Cardiff University.

Novel Technologies to assess Gut Health Claims for Carbohydrates subtheme: Immunobarrier Paul de Vos (UMCG)

Food Choices and Health Stage 1 Research and Analysis Task 4 Reference: Nutrition the Inside Story, HEIA, 2003.

Gut Symmetries: Propertising and Monetising FMT Caroline Wilson, Anura Consulting Ltd

The Salford Healthy Weight Strategy Headline issues and key recommendations.

Key Nutrition Concepts and Terms

Novel Technologies to assess Gut Health Claims for Carbohydrates Subthema: Microbiota Naam trekker: Hauke Smidt Affiliatie: Wageningen Universiteit Contactgegevens:

ESSAYS DUE AT 8:40 AM IN CLASS ON 19 NOVEMBER 2014 –NOTHING CLINICAL AND NOTHING RELATING TO PATHOLOGY NO DEFICIENCIES OR TOXICITIES.

Gut Microbiota: Effects and Benefits

Dr Godfrey Grech University of Malta

JAMA Pediatrics Journal Club Slides: Cesarean Delivery, Formula Feeding, and Intestinal Microbiome of Infants Madan JC, Hoen AG, Lundgren SN, et al. Association.

Session VII WEIGHING IN ON MICROBIOLOGICAL ADI: EXPERIENCES AND PERSPECTIVES Introduction October 26, 2012.

Open Your Mouth & Say “Ah”

The Human Micro-biome. What is the Human Microbiome Microbial communities exist in many places such as in the soil, in the ocean and in every plant and.

Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.

Siri, what should I eat? Zeevi et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell 2015;163(5): Vanessa Ha.

What’s All the Fuss About the Microbiome?

CHALLENGES FOR NUTRITION RESEARCH Focus on Africa

Laurence Macia, PhD 5th European Immunology & Innate Immunity

Working Groups (thematic description)

Relationship with Bile acids and Microbiota

Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney.

Clinical Nutrition Experimental

Robert J. Tomko Jr. Biomedical Sciences

Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches.

Herbert Tilg, Timon E. Adolph Cell Metabolism

Advances in Cystic Fibrosis Views and Perspectives From Basel, Switzerland, 2016.

Probiotics and Infant Feeding with B

Can Your Microbiome Tell You What to Eat?

Microbial Modulation of Insulin Sensitivity

David R. Meldrum, M. D. , Marge A. Morris, M. Ed. , R. D. , C. D. E

Figure 1 Influence of diet on gut microbiota and blood pressure

Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health?

by Laura V. Blanton, Michael J. Barratt, Mark R

It’s in the Milk: Feeding the Microbiome to Promote Infant Growth

Nat. Rev. Rheumatol. doi: /nrrheum

Three major barriers to the integration of metagenomics into pharmacology and toxicology. Three major barriers to the integration of metagenomics into.

Starving our Microbial Self: The Deleterious Consequences of a Diet Deficient in Microbiota-Accessible Carbohydrates Erica D. Sonnenburg, Justin L. Sonnenburg

Stable-Isotope Probing of Human and Animal Microbiome Function

Microbes, Microbiota, and Colon Cancer

David R. Meldrum, M. D. , Marge A. Morris, M. Ed. , R. D. , C. D. E

Experimental approaches.

Disability Intervention Model for Older Adults with Arthritis: An Integration of Theory of Symptom Management and Disablement Process Model So Young.

Relevant Biomarkers of Inflammation and Their Possible Role in Atherosclerosis Arpita Basu, et al. ATVB, 2006; 26;

Biomarkers detected in the serum of rat recipients of intraomental biologic scaffold and intrahepatic syngeneic islets. Biomarkers detected in the serum.

Gut Microbiome Studies

Clinical and contextual characteristics of MNS (n = 490) and MNI (n = 248) Hispanic/Latino adults with type 2 diabetes. Clinical and contextual characteristics.

Transforming medicine with the microbiome

The transition to family foods with higher protein and fiber content correlates with increased gut microbiota diversity. The transition to family foods.

(A) Metabolic niches in the gut microbiome.

Presentation transcript:

Novel Technologies to assess Gut Health Claims for Carbohydrates Subthema: 2 - Characterization of biological effects of carbohydrates Naam trekker: UJF Tietge / HJ Verkade Affiliatie: UMC Groningen/Dept. of Pediatrics Contactgegevens:

We are programmmed for disease General theme: different carbohydrates have differential effects on the balance between health and disease by affecting the intestine at all stages of life aging disease in utero breast milk vs. formula feeding programming food microbiota e.g. SCFA programming food microbiota e.g. SCFA gut health food microbiota e.g. SCFA - direct effects - modulation of programmed risk

Increasing gut health with carbohydrates at all stages of life (13) CH conventional vs. germ-free vs. selective re-constitution/ transplantation Disease models: - atherosclerosis - diabetes (type I and II) - NAFLD/NASH - intest. Inflammation in vivo screening platform biomarkers (disease-causing signatures of metabolites/ bacterial products) novel CHs to test in humans leads for health claims Deliverables programming Techniques: - atherosclerosis quantitation - GTT/ITT/clamps - Histology - histology/clinical symptoms - stable isotopes to quantitate metabolic fluxes - characterization microbiota - barrier function Mouse models Close links to themes 1, 3 and 4 Short-term intervention: - children (lean/obese) - adults (young/elderly/IBD) in vivo screening routine for CHs with human relevance health claims based on established mechanisms novel biomarkers of disease including microbiota establish novel CHs as functional food Deliverables Human studies Techniques: - GTT/clamp - biomarkers -stable isotope techniques - SCFA measurements - histology/clinical symptoms - sampling capsule to characterize: microbiota barrier function ZN Wang et al. Nature 472, (2011) Gut-flora-dependent metabolism of dietary PC and atherosclerosis

(13) CH conventional vs. germ-free vs. selective re-constitution/ transplantation Disease models: - atherosclerosis - diabetes (type I and II) - NAFLD/NASH - intest. Inflammation in vivo screening platform biomarkers (disease-causing signatures of metabolites/ bacterial products) novel CHs to test in humans leads for health claims Deliverables programming Techniques: - atherosclerosis quantitation - GTT/ITT/clamps - Histology - histology/clinical symptoms - stable isotopes to quantitate metabolic fluxes - characterization microbiota - barrier function Mouse models Increasing gut health with carbohydrates at all stages of life

ZN Wang et al. Nature 472, (2011) Gut-flora-dependent metabolism of dietary PC and atherosclerosis

Short-term intervention: - children (lean/obese) - adults (young/elderly/IBD) in vivo screening routine for CHs with human relevance health claims based on established mechanisms novel biomarkers of disease including microbiota establish novel CHs as functional food Deliverables Human studies Techniques: - GTT/clamp - biomarkers - stable isotope techniques - SCFA measurements - histology/clinical symptoms - sampling capsule to characterize: microbiota barrier function (13) CH